How about oscr

**Oscar Health (OSCR) is a stronger candidate for a purchase than Hims & Hers Health (HIMS)**. Here's why: 1. **Recent Performance**: The stock has shown a positive trend, with a percentage change of 1.76% on July 25, 2025. 2. **Technical Indicators**: Oscar Health's resistance level is at $15.92, and the support level is at $14.11. The closing price on July 25, 2025, was $14.45, which is closer to the support level, indicating a potential for price increase as the stock moves towards the resistance level. |code|Ticker|Name|Date|Closing Price|Trading Volume|market_code| |---|---|---|---|---|---|---| |OSCR|OSCR.N|Oscar Health|20250725|14.45|2.7905734E7|169| |code|Ticker|Name|Date|Support Level|Resistance Level|market_code| |---|---|---|---|---|---|---| |OSCR|OSCR.N|Oscar Health|20250724|13.0500|15.9200|169| 3. **Market Sentiment**: There is no recent news of class action lawsuits or regulatory issues that could negatively impact the stock. 4. **Financial Health**: Oscar Health's financial health is not currently under scrutiny, and the company does not have any recent earnings reports that could impact the stock price. In conclusion, Oscar Health (OSCR) appears to be a stronger candidate for a purchase than Hims & Hers Health (HIMS) based on recent performance and technical indicators. However, investors should still conduct their own due diligence before making any investment decisions.